Nectar Lifesci.

Which are the latest news on Nectar Lifesci.?

How big is Nectar Lifesci.?

As of 10th June, Nectar Lifescience Ltd has a market capitalization of 230.00 Cr and reported Net Sales of 7.24 Cr, with a Net Profit loss of 292.89 Cr over the latest four quarters. Shareholder's Funds were 956.11 Cr and Total Assets were 1,992.18 Cr as of March 2025.

As of 10th June, Nectar Lifescience Ltd has a market capitalization of 230.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 7.24 Cr. However, it experienced a loss of 292.89 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds amounted to 956.11 Cr and Total Assets were reported at 1,992.18 Cr.

Who are in the management team of Nectar Lifesci.?

The management team of Nectar Lifesci includes Sanjiv Goyal (Chairman & Managing Director), Ajay Swaroop, Rupinder Tewari, Kuldip Kumar Bhasin, Indu Pal Kaur (all Independent Directors), Meena Verma (Nominee), Anubha (Company Secretary & Compliance Officer), and Puneet Sud (Director of Operations).

The management team of Nectar Lifesci includes the following individuals:<BR><BR>1. **Sanjiv Goyal** - Chairman & Managing Director<BR>2. **Ajay Swaroop** - Independent Director<BR>3. **Meena Verma** - Nominee<BR>4. **Rupinder Tewari** - Independent Director<BR>5. **Anubha** - Company Secretary & Compliance Officer<BR>6. **Kuldip Kumar Bhasin** - Independent Director<BR>7. **Indu Pal Kaur** - Independent Director<BR>8. **Puneet Sud** - Director (Operations)<BR><BR>If you need more details about their roles or responsibilities, feel free to ask!

Who are the peers of the Nectar Lifesci.?

Nectar Lifesci.'s peers include Lyka Labs, Everest Organics, BDH Industries, Kerala Ayurveda, Aarey Drugs, Syschem (India), Brooks Lab., and Sanjiv.Parant. In terms of management risk, growth, and capital structure, BDH Industries and Sanjiv.Parant perform well, while Nectar Lifesci. shows average management risk and below-average growth and capital structure.

Peers: The peers of Nectar Lifesci. are Lyka Labs, Everest Organics, BDH Industries, Kerala Ayurveda, Aarey Drugs, Syschem (India), Brooks Lab., and Sanjiv.Parant.<BR><BR>Quality Snapshot: Excellent management risk is observed at BDH Industries and Sanjiv.Parant, while Average management risk is found at Lyka Labs, Everest Organics, and Nectar Lifesci. Below Average management risk is present at Kerala Ayurveda, Aarey Drugs, Syschem (India), and Brooks Lab. Growth is Good at Syschem (India) and Sanjiv.Parant, while Below Average growth is noted at Lyka Labs, Everest Organics, Nectar Lifesci., Kerala Ayurveda, Aarey Drugs, Brooks Lab., and the rest. Capital Structure is Excellent at BDH Industries, Good at Syschem (India) and Sanjiv.Parant, and Below Average at Lyka Labs, Everest Organics, Nectar Lifesci., Kerala Ayurveda, Aarey Drugs, Brooks Lab., and the rest.<BR><BR>Return Snapshot: BDH Industries has the highest 1-year return at 49.43%, while Kerala Ayurveda has the lowest at -64.05%. Nectar Lifesci.'s 1-year return of -53.54% is better than Kerala Ayurveda's but worse than BDH Industries'. Additionally, the six-month return is negative for Lyka Labs, Everest Organics, Kerala Ayurveda, Nectar Lifesci., Syschem (India), Brooks Lab., and Sanjiv.Parant.

Why is Nectar Lifescience Ltd falling/rising?

As of 10-Jun, Nectar Lifescience Ltd's stock price is at 11.68, down 0.6%, with significant declines of 40.10% year-to-date and 49.66% over the past year. The stock is underperforming compared to the Sensex and is trading below its moving averages, indicating a persistent downward trend and decreased investor confidence.

As of 10-Jun, Nectar Lifescience Ltd's stock price is falling, currently at 11.68, reflecting a change of -0.07 or -0.6%. The stock has experienced significant declines over various periods, with a year-to-date drop of 40.10% and a one-year decrease of 49.66%. In comparison to the benchmark Sensex, which has only fallen by 13.19% year-to-date, Nectar Lifescience Ltd's performance is notably worse.<BR><BR>Additionally, the stock is trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a persistent downward trend. Investor participation has also decreased, as evidenced by a delivery volume of 3.31k on June 9, which is down by 83.78% compared to the 5-day average. This decline in trading activity suggests a lack of confidence among investors, contributing to the stock's falling price. Overall, these factors collectively explain the downward movement in Nectar Lifescience Ltd's stock price.

What does Nectar Lifesci. do?

Nectar Lifescience Ltd is a micro-cap pharmaceutical company specializing in high-quality pharmaceutical products, particularly Cephalosporins. As of March 2026, it reported net sales of 1 Cr and a net loss of 68 Cr, with a market cap of INR 230 Cr.

Overview: <BR>Nectar Lifescience Ltd is an integrated pharmaceutical organization specializing in the manufacturing and delivery of high-quality pharmaceutical products, particularly in the Cephalosporins segment, and operates within the Pharmaceuticals & Biotechnology industry as a micro-cap company.<BR><BR>History: <BR>Nectar Lifescience Ltd was incorporated on June 27, 1995, originally named 'Surya Medicare Limited', and changed its name on March 26, 2004. The latest quarterly results report net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: -68 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 230 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.21 <BR>Return on Equity: -20.51% <BR>Price to Book: 0.39<BR><BR>Contact Details: <BR>Address: Village Saidpura, Tehsil Derabassi S A S Nagar Mohali Punjab : 140507 <BR>Tel: 91-1762-308000 <BR>Email: cs@neclife.com <BR>Website: http://www.neclife.com

Should I buy, sell or hold Nectar Lifescience Ltd?

Are Nectar Lifescience Ltd latest results good or bad?

Nectar Lifescience Ltd's latest results are concerning, showing a consolidated net loss of ₹67.92 crores in Q4 FY26, a significant decline from the previous quarter, with revenues at just ₹1.29 crores. The company's financial health is deteriorating, reflected in a 54.28% drop in stock value over the past year and a low Mojo Score of 9 out of 100, indicating a "STRONG SELL" recommendation.

Nectar Lifescience Ltd's latest results are quite concerning. In Q4 FY26, the company reported a consolidated net loss of ₹67.92 crores, which is a staggering 575.96% decline compared to the previous quarter. The standalone net loss also worsened significantly, going from a profit of ₹0.30 crores in Q3 FY26 to a loss of ₹37.21 crores in Q4 FY26.<BR><BR>Revenue for the quarter was only ₹1.29 crores, a minimal recovery from ₹0.00 crores in the previous quarter, but still far below the ₹5.24 crores generated in Q2 FY26. This erratic revenue pattern indicates severe operational challenges, and the company's operating loss before depreciation, interest, and taxes hit a record low of ₹57.24 crores.<BR><BR>The overall financial health of the company appears to be deteriorating, with a market capitalization of just ₹241 crores and the stock down 54.28% over the past year. The company's Mojo Score stands at a dismal 9 out of 100, categorizing it firmly in "STRONG SELL" territory. <BR><BR>In summary, the latest results reflect a company in crisis, struggling with operational collapse, persistent losses, and a lack of clear pathways to recovery.

When is the next results date for Nectar Lifescience Ltd?

The next results date for Nectar Lifescience Ltd is 30 May 2026.

The next results date for Nectar Lifescience Ltd is scheduled for 30 May 2026.

How has been the historical performance of Nectar Lifesci.?

Nectar Lifesci has experienced significant financial declines, with net sales dropping from 2,782.94 Cr in March 2019 to 1,673.07 Cr in March 2025, and operating profit turning negative with a loss of 26.46 Cr in March 2025. Key metrics, including profit before tax and profit after tax, have also deteriorated, reflecting an overall downward trend in performance.

Answer:<BR>The historical performance of Nectar Lifesci shows significant fluctuations in financial metrics over the years.<BR><BR>Breakdown:<BR>Nectar Lifesci's net sales peaked at 2,782.94 Cr in March 2019 but have since declined, reaching 1,673.07 Cr in March 2025. The total operating income followed a similar trend, decreasing from 2,782.94 Cr in March 2019 to 1,673.07 Cr in March 2025. The company experienced a notable drop in operating profit, with a loss of 26.46 Cr in March 2025 compared to a profit of 166.14 Cr in March 2024. This decline in profitability is reflected in the profit before tax, which fell to -161.53 Cr in March 2025 from a profit of 18.27 Cr in the previous year. The profit after tax also turned negative, resulting in a loss of 113.68 Cr in March 2025, contrasting with a small profit of 4.99 Cr in March 2024. The company's total liabilities decreased from 2,183.58 Cr in March 2024 to 1,992.18 Cr in March 2025, while total assets also declined from 2,183.58 Cr to 1,992.18 Cr in the same period. Cash flow from operating activities was 169 Cr in March 2025, down from 224 Cr in March 2024, indicating a decrease in operational efficiency. Overall, Nectar Lifesci's financial performance has shown a downward trend in key metrics over the past several years.

Who are the top shareholders of the Nectar Lifesci.?

The top shareholders of Nectar Lifesci include individual investors holding approximately 44.12%, with Sanjiv Goyal as the largest promoter at 24.9%. Notably, 99.6% of promoter holdings are pledged, and the highest public shareholder is Jaideep Sampat at 2%.

The top shareholders of Nectar Lifesci include a mix of individual and institutional investors. The majority of the shares are held by non-institutional shareholders, with individual investors holding approximately 44.12% of the company. The promoter with the highest holding is Sanjiv Goyal, who owns 24.9% of the shares. Additionally, there are 17 foreign institutional investors (FIIs) holding about 0.81% of the company. The highest public shareholder is Jaideep Sampat, with a holding of 2%. It's worth noting that a significant portion of the promoter holdings, about 99.5995%, is pledged.

Is Nectar Lifesci. overvalued or undervalued?

As of July 8, 2025, Nectar Lifesciences is considered overvalued and risky due to its negative PE ratio of -3.66 and poor financial metrics compared to peers, alongside a significant year-to-date stock underperformance of -52.49% against the Sensex's 7.13% return.

As of 8 July 2025, Nectar Lifesciences has moved from an attractive to a risky valuation grade. The company appears to be overvalued given its negative PE ratio of -3.66, an EV to EBIT of -11.55, and an EV to EBITDA of -38.76. These figures indicate significant financial distress compared to its peers, such as Sun Pharma, which has a PE ratio of 35.1 and an EV to EBITDA of 24.8, and Cipla, with a PE of 22.8 and an EV to EBITDA of 15.79.<BR><BR>The stark contrast in valuation metrics highlights Nectar Lifesciences' precarious position within the pharmaceuticals and biotechnology industry. Additionally, the company's stock has underperformed significantly against the Sensex, with a year-to-date return of -52.49% compared to the Sensex's 7.13%. This further reinforces the conclusion that Nectar Lifesciences is overvalued in its current state.

Is Nectar Lifesci. technically bullish or bearish?

As of July 7, 2025, the market trend is mildly bearish, influenced by bearish daily moving averages and weekly Bollinger Bands, despite some mildly bullish signals from the MACD and KST, indicating a cautious outlook.

As of 7 July 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven primarily by the daily moving averages indicating bearishness and the weekly Bollinger Bands also showing a mildly bearish signal. The MACD on the weekly timeframe is mildly bullish, which provides some counterbalance, but the overall indicators suggest a lack of strong bullish momentum. The KST is mildly bullish on the weekly but remains bearish on the monthly, further indicating mixed signals. The lack of clear trends in Dow Theory and the OBV being mildly bearish on the monthly reinforce the cautious outlook.

Has Nectar Lifesci. declared dividend?

Nectar Lifescience Ltd has declared a 5% dividend, amounting to 0.05 per share, with an ex-date of September 11, 2020. Despite the dividend declaration, the dividend yield is 0%, and total returns have varied significantly across different periods.

Nectar Lifescience Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.05<BR>- Ex-date: 11 Sep 20<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -26.58%, the dividend return was 0%, resulting in a total return of -26.58%.<BR><BR>For the 1-year period, the price return was -20.92%, the dividend return was 0%, leading to a total return of -20.92%.<BR><BR>Over the 2-year period, the price return was 40.37%, the dividend return was 0%, which resulted in a total return of 40.37%.<BR><BR>In the 3-year period, the price return was -3.98%, the dividend return was 0%, culminating in a total return of -3.98%.<BR><BR>During the 4-year period, the price return was -27.77%, the dividend return was 0%, resulting in a total return of -27.77%.<BR><BR>For the 5-year period, the price return was 67.52%, the dividend return was 0.21%, leading to a total return of 67.73%.<BR><BR>Overall, while Nectar Lifescience Ltd declared a dividend, the dividend yield remains at 0%. The total returns show significant variability, with a notable positive return over the 2-year and 5-year periods, contrasting with negative returns in shorter time frames.